Bristol-Myers Squibb Company (BMY)
62.08 -0.22 (-0.36%)
After hours: 7:55PM EST
- Motley Fool
3 Ways The COVID-19 Pandemic Is Actually Hurting Some Healthcare Stocks
While many healthcare companies are benefiting from the COVID-19 pandemic through the development of vaccines and treatments for the novel coronavirus, others aren't faring nearly as well. In this video from Motley Fool Live recorded on Nov. 30, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com contributor Brian Orelli discuss complications ranging from fewer scheduled surgeries and clinical trial slowdowns to issues with Food and Drug Administration inspections at manufacturing plants. Corinne Cardina: Let's turn now to talk about the effect of the COVID-19 pandemic on some other broad healthcare stocks that might not necessarily be involved in developing coronavirus vaccines or treatments.
- Motley Fool
Got $300? 3 Surefire Stocks to Buy for a Young Bull Market
You've navigated your way through the quickest bear market decline of at least 30% for the broad-based S&P 500. You've also reveled in the fastest rebound to new highs from a bear market low ever. Arguably the only constant this year has been heightened levels of volatility for the stock market.
- Bloomberg
Bristol Myers Deal-Linked Derivative Surges on Inspection Hopes
(Bloomberg) -- The deal sweetener Bristol Myers Squibb Co. offered as a part of its Celgene Corp. purchase spiked as traders positioned ahead of a key year-end deadline and shared optimism related to a needed regulatory inspection.The $9 all-or-nothing payment jumped as much as 55% to the highest level in about three weeks as investors weighed whether U.S. regulators could inspect a facility key to the derivative’s payout in time for a year-end deadline.While traders await word from the company on the state of the inspection, they shared commentary from another drug manufacturer at an Evercore ISI event Wednesday that said a site inspection had just been completed. Fans of the so-called contingent value right, or CVR, viewed the update as a positive sign that the Food and Drug Administration is still inspecting facilities amid the pandemic.The derivative, which has been volatile since plummeting a month ago, depends on FDA approval of the company’s cancer drug lisocabtagene maraleucel by the end of the year as well as approval of a second drug, idecabtagene vicleucel in multiple myeloma, by March 31.Investors have been doing their best to read the tea leaves for what would prove to be a very profitable trade if Bristol Myers can clear the two remaining hurdles. The derivative spiked last week as traders circulated a tweet from FDA Commissioner Stephen Hahn, which signaled the agency is ramping up inspections of drug manufacturing sites.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
